Ratings Indivior PLC

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:27 2025-06-16 EDT			5-day change	1st Jan Change
1,040.00 ^GBX	+1.46%		+2.46%	+1.56%

06-05	UK Market Exodus: Companies that have moved away from a London listing	RE
06-02	PRESS DIGEST-British Business - June 3	RE

Summary: Indivior PLC

The company presents an interesting fundamental situation from a short-term investment perspective.

Highlights: Indivior PLC

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
The company is in a robust financial situation considering its net cash and margin position.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses: Indivior PLC

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings Chart: Indivior PLC

Source: Surperformance

ESG chart: Indivior PLC

Source: MSCI

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Global Valuation (Composite)	Capi.($)
INDIVIOR PLC	-	1.76B
MERCK KGAA		57.77B
KYOWA KIRIN CO., LTD.		9.07B
HALOZYME THERAPEUTICS, INC.		6.64B
YUHAN CORPORATION		5.82B
SK BIOPHARMACEUTICALS CO., LTD.		5.3B
BETTA PHARMACEUTICALS CO., LTD.		3.62B
Average		12.85B
Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

BBB

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes